Literature DB >> 15541215

Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.

Andrew McCullough1.   

Abstract

The purpose of this review is to examine the biologic, pharmacologic, and clinical differences between the three currently approved phosphodiesterase-5 inhibitors to help the clinician make an educated choice about which medication may be best for any individual patient.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15541215     DOI： 10.1007/s11934-004-0070-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  25 in total

Review 1.  Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.

Authors:  Jackie D Corbin; Sharron H Francis; David J Webb
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

2.  Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study.

Authors:  H A Feldman; C B Johannes; C A Derby; K P Kleinman; B A Mohr; A B Araujo; J B McKinlay
Journal:  Prev Med       Date:  2000-04       Impact factor: 4.018

3.  Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

Authors:  Hartmut Porst; Harin Padma-Nathan; François Giuliano; Greg Anglin; Lucio Varanese; Raymond Rosen
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

Review 4.  Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.

Authors:  Allen D Seftel
Journal:  Clin Cardiol       Date:  2004-04       Impact factor: 2.882

5.  Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction.

Authors:  C Stief; H Porst; I Sáenz De Tejada; E Ulbrich; M Beneke
Journal:  Int J Clin Pract       Date:  2004-03       Impact factor: 2.503

Review 6.  Deciphering erectile dysfunction drug trials.

Authors:  John P Mulhall
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

7.  Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial.

Authors:  H Padma-Nathan; V J Stecher; M Sweeney; J Orazem; L-J Tseng; H Deriesthal
Journal:  Urology       Date:  2003-09       Impact factor: 2.649

8.  Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction.

Authors:  René Skoumal; Juza Chen; Krzysztof Kula; Jan Breza; Nicolae Calomfirescu; Bruce R Basson; Vladimir Kopernicky
Journal:  Eur Urol       Date:  2004-09       Impact factor: 20.096

9.  Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.

Authors:  Mitsi A Blount; Alfreda Beasley; Roya Zoraghi; Konjeti R Sekhar; Emmanuel P Bessay; Sharron H Francis; Jackie D Corbin
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

10.  A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.

Authors:  Alexander von Keitz; Jacob Rajfer; Scott Segal; Aileen Murphy; Jonathan Denne; Timothy Costigan; Daniel Lockhart; Charles M Beasley; Jeffrey T Emmick
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.